WO2024059096A3 - C5ar1 antagonists and uses thereof - Google Patents

C5ar1 antagonists and uses thereof Download PDF

Info

Publication number
WO2024059096A3
WO2024059096A3 PCT/US2023/032581 US2023032581W WO2024059096A3 WO 2024059096 A3 WO2024059096 A3 WO 2024059096A3 US 2023032581 W US2023032581 W US 2023032581W WO 2024059096 A3 WO2024059096 A3 WO 2024059096A3
Authority
WO
WIPO (PCT)
Prior art keywords
c5ar1
compounds
antagonists
disorders
receptor
Prior art date
Application number
PCT/US2023/032581
Other languages
French (fr)
Other versions
WO2024059096A2 (en
Inventor
Kevin Hunt
Jianbin Zheng
Sida SHEN
Original Assignee
Vanqua Bio, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanqua Bio, Inc. filed Critical Vanqua Bio, Inc.
Publication of WO2024059096A2 publication Critical patent/WO2024059096A2/en
Publication of WO2024059096A3 publication Critical patent/WO2024059096A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein are compounds that modulate (e.g., antagonize) complement component 5a receptor 1 (C5aR1), a G protein-coupled receptor for C5a that is associated with autoimmune, inflammatory, and neurodegenerative disorders. Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating C5aR1-related diseases and disorders with the compounds in a subject, by administering the compounds and/or compositions described herein.
PCT/US2023/032581 2022-09-14 2023-09-13 C5ar1 antagonists and uses thereof WO2024059096A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263406501P 2022-09-14 2022-09-14
US63/406,501 2022-09-14

Publications (2)

Publication Number Publication Date
WO2024059096A2 WO2024059096A2 (en) 2024-03-21
WO2024059096A3 true WO2024059096A3 (en) 2024-04-25

Family

ID=90275968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/032581 WO2024059096A2 (en) 2022-09-14 2023-09-13 C5ar1 antagonists and uses thereof

Country Status (1)

Country Link
WO (1) WO2024059096A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060052411A1 (en) * 2000-12-28 2006-03-09 Yukio Tada Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor
WO2017014201A1 (en) * 2015-07-17 2017-01-26 富士フイルム株式会社 Nitrogen-containing heterocyclic compound
WO2020240492A1 (en) * 2019-05-31 2020-12-03 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060052411A1 (en) * 2000-12-28 2006-03-09 Yukio Tada Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor
WO2017014201A1 (en) * 2015-07-17 2017-01-26 富士フイルム株式会社 Nitrogen-containing heterocyclic compound
WO2020240492A1 (en) * 2019-05-31 2020-12-03 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE SUBSTANCE RECORD 8 September 2021 (2021-09-08), "2(1H)-Quinolinone,1-(phenylmethyl)-(9CI)", XP093167707, Database accession no. SID 443272799 *

Also Published As

Publication number Publication date
WO2024059096A2 (en) 2024-03-21

Similar Documents

Publication Publication Date Title
MX2021009037A (en) Methods and compositions comprising a 5ht receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders.
JOP20220169A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2022005232A (en) Small molecule degraders of helios and methods of use.
MX2022002877A (en) Hpk1 antagonists and uses thereof.
MX2022008740A (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases.
WO2023288019A3 (en) Lipidated peptide inhibitors of interleukin-23 receptor
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
MX2022000397A (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases.
MX2020014156A (en) Oxadiazoles as agonists of the muscarinic m1 and/or m4 receptor.
WO2020146541A3 (en) Traceless linkers and protein-conjugates thereof
WO2023288017A3 (en) Bicyclic peptide inhibitors of interleukin-23 receptor
MX2021010870A (en) Charged ion channel blockers and methods for use.
MX2023009060A (en) Gpr84 antagonists and uses thereof.
CR20230143A (en) Piperidinyl small molecule degraders of helios and methods of use
BR112022007489A2 (en) AMORPHOUS FORM OF A COMPLEMENT COMPONENT C5A RECEPTOR
WO2024059096A3 (en) C5ar1 antagonists and uses thereof
MX2021011576A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders.
TW202425978A (en) C5ar1 antagonists and uses thereof
MX2023011377A (en) 1,3-substituted cyclobutyl derivatives and uses thereof.
WO2020092102A3 (en) 3-(1h-pyrazol-4-yl)pyridine allosteric modulators of the m4 muscarinic acetylcholine receptor
MX2023002283A (en) Crystalline edg-2 receptor antagonist and methods of making.
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
MX2021009082A (en) Chemical compounds.
WO2023205447A3 (en) Uses of farnesoid x receptor agonists
WO2023278325A8 (en) Bifunctional compounds that degrade alk and uses thereof